[go: up one dir, main page]

GT200100016A - PIRIDO [2,3, -D] PYRIMIDIN-2,7-INHIBITING DIAMINES OF KINASES. - Google Patents

PIRIDO [2,3, -D] PYRIMIDIN-2,7-INHIBITING DIAMINES OF KINASES.

Info

Publication number
GT200100016A
GT200100016A GT200100016A GT200100016A GT200100016A GT 200100016 A GT200100016 A GT 200100016A GT 200100016 A GT200100016 A GT 200100016A GT 200100016 A GT200100016 A GT 200100016A GT 200100016 A GT200100016 A GT 200100016A
Authority
GT
Guatemala
Prior art keywords
pirido
diamines
pyrimidin
kinases
inhibiting
Prior art date
Application number
GT200100016A
Other languages
Spanish (es)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Vara Prasad Venkata Nagendra Josyula
Dennis Joseph Mcnamara
Peter Laurence Toogood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100016A publication Critical patent/GT200100016A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

ESTA INVENCION SE REFIERE A PIRIDO[2,3,D]PIRIMIDIN2,7DIAMINAS QUE INHIBEN ENZIMAS DE SERINA/TREONINACINASAS DEPENDIENTES DE CICLINA Y ENZIMAS DE TIROSINACINASA MEDIADAS POR FACTOR DE CRECIMIENTO, Y COMO TALES SON UTILES PARA TRATAR ENFERMEDADES Y TRASTORNOS DE LA PROLIFERACION CELULAR. ESTA INVENCION PROPORCIONA, ADEMAS UN METODO PARA TRATAR TRASTORNOS POLIFERATIVOS CELULARES, TAMBIEN PROPORCIONA LA PRESENTE INVENCION UNA COMPOSICION FARMACEUTICAMENTE ACEPTABLE QUE CONTIENE UN COMPUESTO DE FORMULA (I), EN DONDE R2, R5, R6, R7 Y R8 SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE.THIS INVENTION REFERS TO PIRIDO [2,3, D] PYRIMIDIN2,7 DIAMINES THAT INHIBIT SERINE / THREONINACINase CYCLINE ENZYMES AND THYROSINACINASE ENZYMES MEDIATED BY GROWTH FACTOR, AND AS SUCH PROBLEMS FOR PROCESSING . THIS INVENTION PROVIDES, IN ADDITION TO A METHOD TO TREAT CELLULAR POLYFERATIVE DISORDERS, IT ALSO PROVIDES THE PRESENT INVENTION A PHARMACEUTICALLY ACCEPTABLE COMPOSITION CONTAINING A FORMULA COMPOUND (I), WHERE R2, R5, R6, R7, R7, R7, R7, R7, R7, R7 .

GT200100016A 2000-01-25 2001-01-23 PIRIDO [2,3, -D] PYRIMIDIN-2,7-INHIBITING DIAMINES OF KINASES. GT200100016A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
GT200100016A true GT200100016A (en) 2001-10-19

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100016A GT200100016A (en) 2000-01-25 2001-01-23 PIRIDO [2,3, -D] PYRIMIDIN-2,7-INHIBITING DIAMINES OF KINASES.

Country Status (34)

Country Link
EP (1) EP1254137A1 (en)
JP (1) JP4047010B2 (en)
KR (1) KR20020065939A (en)
CN (1) CN1395578A (en)
AP (1) AP2002002586A0 (en)
AR (1) AR030044A1 (en)
AU (1) AU2542501A (en)
BG (1) BG106850A (en)
BR (1) BR0107751A (en)
CA (1) CA2397961C (en)
CO (1) CO5261549A1 (en)
CR (1) CR6706A (en)
CZ (1) CZ20022475A3 (en)
DZ (1) DZ3266A1 (en)
EA (1) EA200200643A1 (en)
EE (1) EE200200405A (en)
GT (1) GT200100016A (en)
HN (1) HN2001000013A (en)
HU (1) HUP0204141A3 (en)
IL (1) IL150545A0 (en)
IS (1) IS6443A (en)
MA (1) MA26868A1 (en)
MX (1) MXPA02007221A (en)
NO (1) NO20023527L (en)
OA (1) OA12161A (en)
PA (1) PA8510701A1 (en)
PE (1) PE20011066A1 (en)
PL (1) PL356802A1 (en)
SK (1) SK10632002A3 (en)
SV (1) SV2002000294A (en)
TN (1) TNSN01014A1 (en)
WO (1) WO2001055147A1 (en)
YU (1) YU50402A (en)
ZA (1) ZA200205879B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
BR0114829A (en) 2000-10-23 2003-09-23 Smithkline Beecham Corp New compounds
PE20030008A1 (en) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co DUAL INHIBITORS OF PDE 7 AND PDE 4
JP4603268B2 (en) 2002-04-19 2010-12-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New compounds
PL377795A1 (en) * 2002-11-28 2006-02-20 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
WO2006032452A1 (en) * 2004-09-21 2006-03-30 F. Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors
WO2006104917A2 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
US7423042B2 (en) 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
TWI389690B (en) 2005-03-25 2013-03-21 Glaxo Group Ltd Novel compounds
FR2887882B1 (en) 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
CA2614443C (en) * 2005-07-21 2011-03-22 F. Hoffmann-La Roche Ag Pyrido [2,3-d] pyrimidine-2,4-diamine compounds as ptp1b inhibitors
ES2351939T3 (en) * 2005-08-09 2011-02-14 Irm Llc COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASES.
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (en) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co MAPK/ERK Kinase Inhibitors
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2010063352A1 (en) * 2008-12-01 2010-06-10 Merck Patent Gmbh 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
EP2968331B1 (en) * 2013-03-14 2020-07-01 Icahn School of Medicine at Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (en) * 2014-09-02 2016-11-02 한국원자력의학원 Pyrimidine derivatives having anti-cancer effect, combination therapeutic effect with radiation, and anti-diabetic effect, and PPAR activity, and medical use thereof
CN107286180B (en) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 Heteropyridopyrimidinone derivatives as CDK inhibitors and their applications
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
RU2191188C2 (en) * 1994-11-14 2002-10-20 Варнер-Ламберт Компани Derivatives of 6-arylpyrido[2,3-d]pyrimidines and -naphthyridines, pharmaceutical composition showing inhibitory effect on cellular proliferation induced by protein tyrosine kinase and method of inhibition of cellular proliferation
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
EA003640B1 (en) * 1998-05-26 2003-08-28 Варнер-Ламберт Компани Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

Also Published As

Publication number Publication date
SK10632002A3 (en) 2003-06-03
NO20023527D0 (en) 2002-07-24
EA200200643A1 (en) 2002-12-26
MXPA02007221A (en) 2002-11-29
HN2001000013A (en) 2001-06-18
AP2002002586A0 (en) 2002-09-30
ZA200205879B (en) 2003-09-29
BR0107751A (en) 2002-11-12
AR030044A1 (en) 2003-08-13
CA2397961A1 (en) 2001-08-02
CA2397961C (en) 2008-08-26
HUP0204141A2 (en) 2003-04-28
TNSN01014A1 (en) 2005-11-10
SV2002000294A (en) 2002-07-16
PA8510701A1 (en) 2002-12-11
BG106850A (en) 2003-02-28
IS6443A (en) 2002-06-25
HUP0204141A3 (en) 2005-03-29
PE20011066A1 (en) 2001-10-22
CO5261549A1 (en) 2003-03-31
KR20020065939A (en) 2002-08-14
PL356802A1 (en) 2004-07-12
NO20023527L (en) 2002-09-10
EP1254137A1 (en) 2002-11-06
AU2542501A (en) 2001-08-07
DZ3266A1 (en) 2001-08-02
MA26868A1 (en) 2004-12-20
IL150545A0 (en) 2003-02-12
CZ20022475A3 (en) 2003-03-12
EE200200405A (en) 2003-12-15
JP4047010B2 (en) 2008-02-13
CR6706A (en) 2005-04-04
OA12161A (en) 2006-05-08
YU50402A (en) 2005-11-28
JP2003523357A (en) 2003-08-05
CN1395578A (en) 2003-02-05
WO2001055147A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
GT200100016A (en) PIRIDO [2,3, -D] PYRIMIDIN-2,7-INHIBITING DIAMINES OF KINASES.
TW200510380A (en) Mitotic kinesin inhibitors
DE60231439D1 (en) MITOTIC KINESINE HEMMER
DE60234278D1 (en) MITOTIC KINESINE HEMMER
WO2003050064A3 (en) Mitotic kinesin inhibitors
WO2003049527A3 (en) Mitotic kinesin inhibitors
WO2003050122A3 (en) Mitotic kinesin inhibitors
GEP20053660B (en) Novel Tyrosine Kinase Inhibitors
IL165624A0 (en) Mitotic kinesin inhibitors
AU2003225800A1 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
PL1664026T3 (en) Mitotic kinesin inhibitors
WO2003039460A3 (en) Mitotic kinesin inhibitors
WO2004037171A3 (en) Mitotic kinesin inhibitors
ZA200704476B (en) Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
DE60329990D1 (en) MITOTIC KINESINE HEMMER
WO2005017190A3 (en) Mitotic kinesin inhibitors
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2005018547A3 (en) Mitotic kinesin inhibitors
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2005065183A3 (en) Mitotic kinesin inhibitors
YU75603A (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
IL151692A0 (en) Polyamine analogues as cytotoxic agents